Skip to main content
main-content

11-01-2021 | Dapagliflozin | Commentary | Video

PRESERVED-HF: Support for dapagliflozin to improve HFpEF health status

Mikhail Kosiborod outlines the findings from the PRESERVED-HF trial, demonstrating that dapagliflozin improves symptoms and physical function in people with heart failure with preserved ejection fraction, and discusses the promise of SGLT2 inhibitors for meeting the treatment goals in this population (9:35). 

00:00 Introduction
02:12 Key findings from PRESEVED-HF
04:42 How dapagliflozin compares with other HFpEF medications
07:08 Conclusions so far on SGLT2 inhibitors in HFpEF

EASD Annual Meeting 2021 coverage

Access all of our ongoing coverage including the latest news and expert video interviews.

New additions to the Adis Journal Club

A selection of topical peer-reviewed articles from the Adis journals, curated by the editors.

Image Credits